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Does additional linear ablation after circumferential
pulmonary vein isolation improve clinical outcome
in patients with paroxysmal atrial ﬁbrillation?
Prospective randomised study
Hee-Sun Mun, Boyoung Joung, Jaemin Shim, Hye Jin Hwang, Jong Youn Kim,
Moon-Hyoung Lee, Hui-Nam Pak
ABSTRACT
Objective Circumferential pulmonary vein isolation (CPVI)
has been considered the cornerstone of radiofrequency
catheter ablation (RFCA) for atrial ﬁbrillation (AF).
However, it is unclear whether linear ablation in addition
to CPVI improves clinical outcome.
Design Prospective randomised study to compare the
efﬁcacy of CPVI and CPVI with additional linear ablation in
patients with paroxysmal AF (PAF).
Setting University hospital.
Patients This study enrolled 156 patients (male 76.3%,
55.8611.5 years old (mean6SD)) who underwent RFCA
for PAF.
Interventions CPVI (n¼52), CPVI+roof line (CPVI+RL;
n¼52) and CPVI+RL+posterior inferior line (CPVI
+PostBox; n¼52).
Main outcome measures Procedure time, ablation
time and clinical outcome.
Results (1) The CPVI group showed shorter total
procedure time (180.4639.5 min vs 189.6629.0 min
and 201.7651.7 min, respectively (mean6SD);
p¼0.035) and ablation time (4085.561384.1 s vs
5253.561010.9 s and 5495.061316.0 s, respectively;
p<0.001) than the CPVI+RL and CPVI+PostBox groups.
(2) During 15.665.0 months of follow-up, the recurrence
rates 3 months after RFCA were 11.5% in CPVI, 21.2% in
CPVI+RL and 19.2% in CPVI+PostBox (p¼0.440). (3)
The achievement rate of CPVI was 100.0%, and
bidirectional block rate was 80.8% in CPVI+RL and
59.6% in CPVI+PostBox. The clinical recurrence rates
with or without achieving bidirectional block were not
signiﬁcantly different from each other (p¼0.386).
Conclusion In patients with PAF, linear ablation in
addition to CPVI did not improve clinical outcome,
regardless of bidirectional block achievement, while it
prolonged the total procedure and ablation time.
INTRODUCTION
As atrial ﬁbrillation (AF) begets AF,
1 early inter-
vention against AF at the stage of paroxysmal AF
(PAF) may improve clinical outcome, and radio-
frequency catheter ablation (RFCA) can be consid-
ered as a ﬁrst-line rhythm-control strategy in
patients without any structural heart disease.
2
Circumferential pulmonary vein isolation (CPVI)
has been considered the cornerstone of AF catheter
ablation, especially in patients with PAF.
3e9
However, there is still a substantial recurrence rate.
To improve outcomes, an additional ablation to
CPVI has been suggested to modify the substrate
for AF.
10e14 However, ablation strategies are still
under investigation, and reports of randomised
trials comparing ablation strategies for PAF in
structurally normal heart are limited.
15 Therefore
we hypothesised that an additional linear ablation
to CPVI may reduce clinical recurrence of AF after
RFCA. We compared three different ablation
designs in a prospective randomised study: CPVI,
CPVI+roof line (CPVI+RL) and CPVI+RL
+posterior inferior line (CPVI+PostBox). The
purpose of this study was to compare these three
ablation strategies in terms of procedure time,
efﬁcacy or safety, and clinical outcome, and eval-
uate whether achievement of bidirectional block
improves clinical outcome in patients with PAF.
METHODS
Patient selection
The study protocol was approved by the institu-
tional review board of Severance Hospital of Yonsei
University. All patients provided written informed
consent. The study enrolled 156 patients who
underwent RFCA for symptomatic drug-refractory
PAF. Exclusion criteria were: (1) permanent or
persistent AF; (2) left atrium (LA) size >55 mm on
echocardiogram; (3) associated structural heart
disease other than left ventricular (LV) hyper-
trophy; (4) intracardiac thrombi; (5) LV ejection
fraction <45%; (6) AF with rheumatic valvular
disease; (7) previous AF ablation; (8) history of
cardiac surgery. The patients were prospectively
and randomly assigned to three groups according to
the method of RFCA: CPVI alone (CPVI; n¼52);
linear ablation at the LA roof in addition to CPVI
(CPVI+RL; n¼52); and linear ablation at the
posterior inferior LA wall in addition to CPVI and
RL (CPVI+PostBox; n¼52). We chose the sample
size on the basis of a statistical analysis to prove
the superiority of CPVI with additional linear
ablation, which was described in a previous study
comparing ablation strategies in patients with
PAF.
12 All antiarrhythmic drugs (AADs) were
discontinued more than ﬁve half-lives before the
procedure. Patients taking amiodarone before the
procedure stopped taking it at least 4 weeks before.
Anticoagulation therapy was maintained for
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Heart rhythm disordersa target prothrombin time international normalised ratio (INR)
of 2.0e3.0 at least 4 weeks before the procedure and continued
until the day of the procedure. Both trans-thoracic echocardi-
ography and trans-oesophageal echocardiography were
performed before the procedure to determine whether patients
had combined structural heart disease or LA thrombus. We
imaged all patients with three-dimensional (3D) spiral CT (64
Channel, Light Speed Volume CT, Philips, Brilliance 63,
Amsterdam, The Netherlands) to visually deﬁne the anatomy of
the LA and pulmonary veins (PVs).
Electrophysiological mapping procedure
Intracardiac electrograms were recorded using the Prucka
CardioLab Electrophysiology system (General Electric Medical
Systems, Milwaukee, Wisconsin, USA), and RFCA was
performed on all patients using 3D electroanatomical mapping
(NavX; St Jude Medical, Minnetonka, Minnesota, USA) merged
with 3D spiral CT. The high right atrium (RA), low RA and
coronary sinus were mapped with a decapolar catheter (Bard
Electrophysiology, Lowell, Massachusetts, USA) and duo-
decapolar catheter (St Jude Medical) inserted via the left femoral
vein. A quadripolar catheter was also placed in the superior vena
cava. Double trans-septal punctures were performed, and multi-
view pulmonary venograms were obtained. After trans-septal
access had been secured, a circumferential PV mapping catheter
(Lasso; Biosense-Webster, Diamond Bar, California, USA) was
introduced with the use of a long sheath (Schwartz left 1; St
Jude Medical). Systemic anticoagulation was achieved with
intravenous heparin to maintain an activated clotting time of
350e400 s during the procedure. For electroanatomical mapping,
the 3D geometry of both the LA and PV was generated using the
NavX system and then merged with the 3D spiral CT images. To
avoid inadvertent collateral injury, the oesophagus was visual-
ised by barium swallow and displayed on the monitor during the
ablation procedure.
Radiofrequency catheter ablation
For CPVI ablation, continuous circumferential lesions were
created at the level of the LA antrum (about 2 cm from the PV
ostia) encircling the right and left PV guided by the NavX
system using an open irrigation 3.5 mm tip deﬂectable catheter
(Celsius; Johnson & Johnson, Diamond Bar, California, USA;
irrigation ﬂow rate 20e30 ml/min; 30 W; 478C; ﬁgure 1A). The
end point of CPVI was electrical isolation of PV potentials,
which was conﬁrmed by Lasso catheter mapping during sinus
rhythm, RA pacing, and/or isoproterenol infusion after 30 min.
The RL was created on the LA roof connecting the tops of two
encircling lesions (irrigation ﬂow rate 30 ml/min; 35 W; 478C;
ﬁgure 1B), and achievement of bidirectional block was conﬁrmed
by pacing from the LA appendage and LA posterior wall.
16 The
PostBox lesion was generated by an additional posterior inferior
line connecting the lower margins of the right and left CPVI
lines (irrigation ﬂow rate 25 ml/min; 30 W; 478C) to the RL
(ﬁgure 1C), and achievement of the bidirectional block was
conﬁrmed by the absence of potential in the posterior venous
atrium.
Post-ablation management and follow-up
After RFCA, the patients were followed up at the outpatient
clinic at 1, 3, 6, 9 and 12 months and then every 6 months
thereafter. ECG was performed at each visit. The Holter monitor
(24 h or 48 h) and/or event recorder were evaluated 3, 6 and
12 months after RFCA.
19 Whenever the patient reported
symptoms of palpitations suggestive of arrhythmia recurrence,
Holter monitor or event monitor recordings were obtained. We
deﬁned early recurrence as any episode of AF or atrial tachy-
cardia of at least 30 s in duration that occurred within 3 months
of the blanking period after RFCA. Warfarin was administered to
all patients for at least 3 months after RFCA, targeting an INR
of 2.0e3.0. All patients underwent follow-up echocardiography
12 months after RFCA or at any time the patient had cardiac
symptoms. No patient was taking AAD at discharge after
an RFCA procedure. AAD was prescribed for patients with
ECG-documented AF recurrence or highly symptomatic
ECG-documented frequent atrial premature beats.
Data analysis
Continuous variables are expressed as the mean6SD and were
compared by analysis of variance. Categorical variables were
compared by the c
2 test. When a pairwise c
2 test was used for
three groups, the p value threshold for statistical signiﬁcance
was adjusted to address type I error inﬂation for multiple
comparisons (p value <0.017). The Tukey test was performed
for post hoc analyses. A KaplaneMeier analysis was used
to determine the probability of freedom from arrhythmia
recurrence after RFCA. p<0.05 was considered signiﬁcant.
RESULTS
Patient characteristics
The patients were prospectively and randomly assigned to
undergo CPVI (n¼52), CPVI+RL (n¼52) or CPVI+PostBox
(n¼52). The mean age was 55.8611.5 years, and 119 patients
(76.3%) were male. Table 1 summarises patient characteristics
by groups. CHADS2 score was 0.7660.99. The patients with
hypertension accounted for 42.9%, and those with diabetes
11.5%. A history of ischaemic stroke was found in 7.7%, and the
Figure 1 The ablation lesions for the
three strategies. (A) For circumferential
pulmonary vein isolation (CPVI)
ablation, continuous circumferential
lesions were created at the level of the
left atrial (LA) antrum (about 2 cm from
the pulmonary vein (PV) ostia)
encircling the right and left PV. (B) In
addition to CPVI, the roof line (RL) was
created on the LA roof connecting the
tops of two encircling lesions. (C) In
addition to CPVI+RL, the PostBox lesion
was generated by additional posterior
inferior line connecting the lower margins
of the right and left CPVI lines.
Heart 2012;98:480e484. doi:10.1136/heartjnl-2011-301107 481
Heart rhythm disordersmean LA anterioreposterior diameter measured by echocardi-
ography was 40.1364.98 mm. The three ablation groups
were well balanced with regard to demographic and baseline
characteristics.
Procedural results and clinical outcomes
Table 2 summarises the procedural results and complications.
The total procedure time (p¼0.035) and radiofrequency energy
delivery time (p<0.001) were signiﬁcantly shorter in the CPVI
group than the CPVI+RL or CPVI+PostBox groups. The
procedure-related complication rate was 3.8%. Only one patient,
who was in the CPVI+RL group, had a major complication and
that was a transient ischaemic attack. A complication in one
patient with pericardial effusion spontaneously resolved
without pericardiocentesis, and complications in four patients
with pericarditis were controlled by steroid (table 2). There was
no difference in the complication rate among the three groups.
The early recurrence rate within 3 months of RFCA was not
signiﬁcantly different among the three groups (p¼0.384).
During 15.665.0 months of follow-up, the clinical recurrence
rate 3 months after RFCA was 11.5% in the CPVI group, 21.2%
in the CPVI+RL group and 19.2% in the CPVI+PostBox group
(p¼0.440; table 2). Figure 2 displays KaplaneMeier analysis of
arrhythmia recurrence-free survival, and there was no signiﬁcant
difference among the three ablation strategies. In the ECG
presentation at the time of recurrence, the proportions of atrial
tachycardia were 33.3% in CPVI, 54.5% in CPVI+RL and 70.0%
in CPVI+PostBox (p¼0.359).
Complete conduction block of linear ablation and clinical
outcome
We achieved CPVI (n¼52) in all patients (100%), and bidirec-
tional block in 80.8% of CPVI+RL (n¼42) and 59.6% of CPVI
+PostBox (n¼31, p<0.001, table 3). The overall clinical recur-
rence rates with and without achievement of bidirectional block
were not signiﬁcantly different (16.0% vs 22.6%, p¼0.386). In
patients in whom bidirectional block was achieved by linear
ablations, there was no signiﬁcant difference in the early recur-
rence rate (21.2%, 28.6% and 19.4%, respectively, p¼0.589) and
in the clinical recurrence rate 3 months after RFCA (11.5%,
19.1% and 19.4%, respectively, p¼0.978; table 3). The rate of
AAD utilisation in patients in whom bidirectional block was
achieved tended to be higher in the CPVI+RL (28.6%) group
than the CPVI (19.2%) or CPVI+PostBox (19.4%) groups
without signiﬁcance (p¼0.500).
DISCUSSION
In this prospective randomised comparison trial for the appro-
priate ablation strategy of PAF, we demonstrated that additional
linear ablations to CPVI did not improve clinical outcome in
spite of longer procedure or ablation time, and regardless of
bidirectional block achievement. The clinical recurrence rate was
also not signiﬁcantly different between patients with complete
conduction block by additional linear ablation and those with
incomplete conduction block.
Mechanism and effectiveness of CPVI in patients with PAF
Compared with segmental ostial ablation, CPVI targets peri-PV
ostial triggers or drivers, ganglionated plexi and critical mass
reduction,
17 18 as well as PV triggers. However, there is still
a1 0 e20% recurrence rate after CPVI even in patients with
Table 1 Baseline clinical characteristics
CPVI
(n[52)
CPVI+RL
(n[52)
CPVI+PostBox
(n[52) p Value
Age (years) 54.88612.66 58.25610.78 54.27610.62 0.162
Male 37 (71.2) 41 (78.8) 41 (78.8) 0.567
CHADS2 0.7160.94 0.7160.90 0.8761.14 0.661
Heart failure 1 (1.9) 1 (1.9) 1 (1.9) 1.000
Hypertension 21 (40.4) 24 (46.2) 22 (42.3) 0.833
Age >75 years 2 (3.8) 3 (5.8) 0 (0) 0.235
Diabetes 7 (13.5) 3 (5.8) 8 (15.4) 0.267
Stroke 2 (3.8) 3 (5.8) 7 (13.5) 0.150
LA diameter (mm) 39.2965.18 40.4264.28 40.6765.40 0.322
EF (%) 64.7165.98 63.7967.63 63.7366.59 0.710
E/E’ 9.8662.73 9.6263.63 9.6863.63 0.936
Data are expressed as number (%) of patients or mean6SD.
CPVI, circumferential pulmonary vein isolation; E/E’, ratio of mitral valve inﬂow and tissue
Doppler; EF, ejection fraction; LA, left atrium; PAF, paroxysmal atrial ﬁbrillation; PostBox,
additional RL and posterior inferior line; RL, LA roof line.
Table 2 Procedural results and clinical outcomes
CPVI (n[52) CPVI+RL (n[52) CPVI+PostBox (n[52) p Value
Total procedure time (min) 180.43639.52* 189.62628.95 201.69651.69* 0.035
Ablation time (s) 4085.561384.1yz 5253.561010.9y 5495.061316.0z <0.001
Complications 2 (3.8) 1 (1.9) 3 (5.8) 0.595
Transient ischaemic attack 0 (0) 1 (1.9) 0 (0) 0.366
Pericardial effusion 1 (1.9) 0 (0) 0 (0) 0.366
Pericarditis 1 (1.9) 0 (0) 3 (5.8) 0.166
Clinical outcomes
Follow-up duration (min) 16.1764.34 15.9064.53 14.6965.90 0.273
ER rate 11 (21.2) 18 (34.6) 15 (28.8) 0.384
ER rate without AAD 8 (15.4) 16 (30.8) 14 (26.9) 0.164
ER rate with AAD 3 (5.8) 2 (3.8) 1 (1.9) 0.595
Patients taking AAD 18 (34.6) 17 (32.7) 22 (42.3) 0.560
CR rate 6 (11.5) 11 (21.2) 10 (19.2) 0.440
CR rate without AAD 5 (9.6) 9 (17.3) 7 (13.5) 0.517
CR rate with AAD 1 (1.9) 2 (3.8) 3 (5.8) 0.595
Patients taking AAD 10 (19.2) 14 (26.9) 15 (28.8) 0.221
Data are expressed as number (%) of patients or mean6SD.
*p¼0.026, CPVI versus CPVI+PostBox.
yp<0.001, CPVI versus CPVI+RL.
zp<0.001, CPVI versus CPVI+PostBox.
AAD, antiarrhythmic drug; CPVI, circumferential pulmonary vein isolation; CR, clinical recurrence; ER, early recurrence; PostBox, additional RL and posterior inferior line; RL, LA roof line.
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19 Therefore additional linear ablations or complex frac-
tionated atrial electrogram (CFAE)-guided ablation have been
tried to reduce such AF recurrence after RFCA in selected
patients with PAF-like long-standing persistent AF.
20e23
However, there was no consensus over the effectiveness of
additional linear ablations to CPVI in PAF ablation. In this study,
we found no additional beneﬁt of linear ablation in addition to
CPVI in patients with PAF. Therefore, to improve clinical
outcome after PAF catheter ablation, we should focus on how to
reduce long-term PV reconnection after initially successful PV
isolation,
24 not how to ablate more, at least in patients with
a structurally normal heart.
Why did linear ablation not change the success rate?
In 1993, Swartz initially described a catheter-based technique for
linear ablation of long-standing persistent AF (AHA abstract,
Circulation 1993;90:335).
25 Linear ablation eliminates more atrial
substrates and partially compartmentalises the atria to prevent
the formation of macro-re-entrant circuits which have been
proposed to maintain AF.
16 A stepwise approach to add linear
ablations or CFAE-guided ablation has been known to be
effective for AF substrate modiﬁcation and improving clinical
outcome.
10e14 26 While AF ablation was performed step by step,
AF frequency spectra were organised as increments of linear
ablation lesions and ﬁnally terminated.
27 This ﬁnding suggests
that stepwise reduction of atrial critical mass organises AF, and
biantral ablation and posterior wall isolation reduce critical mass
by 17% and 32%, respectively (unpublished data). However,
critical mass reduction by linear ablation did not work in
patients with PAF in this study and another non-randomised
study.
28 This may be because the critical mass after CPVI
was too small to maintain AF in patients with less remodelled
PAF, or additional linear ablation may rather potentially be
proarrhythmic.
28
How to improve clinical outcome of PAF ablation?
Previous studies on AF ablation have highlighted the proar-
rhythmic effect of incomplete and recovered gaps.
6e8 10e13
Therefore, we need to ﬁnd better methods of attaining durable
PVI, rather than ablating more. Other biological factors that
potentially contribute to conduction recovery, such as haema-
topoietic progenitor cell mobilisation
29 30 or myoﬁbroblasts,
31
should be considered in the future. Another point we need to
consider is the deﬁnition of recurrence after AF catheter ablation.
The current deﬁnition of AF recurrence does not consider the
reduction of AF burden.
2
Study limitations
This single-centre study included a relatively small number of
patients. Asymptomatic and low frequent recurrence of AF may
have been undetected by this study protocol. We did not
quantify the change in AF burden in patients with PAF. Our
ablation design for CPVI was close to PV ostial ablation.
However, we do not think it would change the ﬁnding that
linear ablation did not improve clinical outcome in patients with
PAF with small LA. The clinical outcome of the CPVI+PostBox
group may have been affected by low achievement of bidirec-
tional block in an effort to avoid potential oesophageal injury
during posterior inferior linear ablation on the LA posterior wall.
Therefore further study with a larger number of patients or
more intensive ECG follow-up is warranted. Because of the
importance of permanent PVI and potentially proarrhythmic
effects of inadvertent substrate modiﬁcation, this type of rand-
omised study would be clinically relevant for patients with
persistent AF.
CONCLUSION
We conducted the ﬁrst prospective randomised comparison
study for an appropriate ablation strategy for PAF and demon-
strated that additional linear ablations to CPVI did not improve
clinical outcome despite longer procedure or ablation time, and
regardless of bidirectional block achievement.
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Figure 2 KaplaneMeier analysis of arrhythmia recurrence-free rate in
patients with paroxysmal atrial ﬁbrillation subjected to three ablation
strategies. There was no signiﬁcant difference among the three ablation
strategies (p¼0.31 by the use of the log rank (Mantel-Cox) test). CPVI,
circumferential pulmonary vein isolation; PostBox, additional RL and
posterior inferior line; RL, left atrial roof line.
Table 3 Clinical outcomes in patients with achievement of bidirectional
block
CPVI CPVI+RL CPVI+PostBox p Value
Conduction block rate 52 (100%)* 42 (80.8%)y 31 (59.6%)* y <0.001
ER rate 11 (21.2%) 12 (28.6%) 6 (19.4%) 0.589
ER rate without AAD 8 (15.4%) 10 (23.8%) 5 (16.1%) 0.538
ER rate with AAD 3 (5.8%) 2 (4.8%) 1 (3.2%) 0.871
Patients taking AAD 18 (34.6%) 12 (28.6%) 8 (25.8%) 0.666
LR rate 6 (11.5%) 8 (19.1%) 6 (19.4%) 0.978
LR rate without AAD 5 (9.6%) 6 (14.3%) 3 (9.7%) 0.739
LR rate with AAD 1 (1.9%) 2 (4.8%) 3 (9.7%) 0.279
Patients taking AAD 10 (19.2%) 12 (28.6%) 6 (19.4%) 0.500
Data are expressed as number (percentages) of patients.
*p¼0.001, CPVI versus CPVI+RL.
yp<0.001, CPVI versus CPVI+PostBox.
AAD, antiarrhythmic drug; CPVI, circumferential pulmonary vein isolation; ER, early
recurrence; LR, late recurrence; PostBox, additional RL and posterior inferior line; RL, LA
roof line.
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